B
Bullisch
Bullisch · 25%ELVN
$25.90
Szenariopreis
$41.820
+0.577 (+1.38%)Zum Schluss
Loading chart…
- Hoch
- 42.920
- Eröffnung
- 41.760
- Volumengewichteter Durchschnittskurs
- 42.11
- Volumen
- 2.05M
- Marktkap.
- 1.10B
- Tief
- 41.585
- Umsatz
- 86.43M
- EV/EBITDA, TTM
- 0.00
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. It is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, and pursuing several additional research stage opportunities that align with its development approach. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia (CML). ELVN-001 is an adenosine triphosphate (ATP)-competitive tyrosine kinase inhibitor (TKI). The Company's second product candidate, ELVN-002, is a potent, highly selective, central nervous system penetrant and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against wild type HER2 and various HER2 mutations.
KI-Analyse of Enliven Therapeutics Inc (ELVN)
KaufenEnliven Therapeutics Inc is a good buy right now due to its strong cash reserves of $895.2 million, which ensures liquidity into 2030, and a current price of $37.32 significantly below analyst price targets ranging from $70 to $82. The main risk is the negative earnings trend, with an EPS of -0.49 reported last quarter, missing expectations by $0.10.
Bewertungskennzahlen
Das aktuelle erwartete KGV von Enliven Therapeutics Inc (ELVN) beträgt 0.00, verglichen mit dem 5-Jahres-Durchschnitt von -9.29.
Alphio-AI-Kursszenarien für ELVN
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.
Whales, die ELVN halten
Event-Zeitleiste
News
5.010-14PRnewswireEnliven Appoints New Board Member Ahead of Phase 3 Trial
9.010-06NewsfilterEnliven on Track to Initiate ENABLE-2 Trial by Year-End 2026
6.010-02CNBCLatest Ratings and Outlook from Wall Street
6.010-01CNBCLatest Wall Street Rating Updates
1.009-03PRnewswireEnliven Therapeutics Announces Upcoming Investor Conference Participation
ELVN FAQ – beantwortet von Alphio AI
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. It is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, and pursuing several additional research stage opportunities that align with its development approach. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia (CML). ELVN-001 is an adenosine triphosphate (ATP)-competitive tyrosine kinase inhibitor (TKI). The Company's second product candidate, ELVN-002, is a potent, highly selective, central nervous system penetrant and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against wild type HER2 and various HER2 mutations. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Enliven Therapeutics Inc is a good buy right now due to its strong cash reserves of $895.2 million, which ensures liquidity into 2030, and a current price of $37.32 significantly below analyst price targets ranging from $70 to $82. The main risk is the negative earnings trend, with an EPS of -0.49 reported last quarter, missing expectations by $0.10.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenDiese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.